CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 744,313	$ 535,203
Marketable securities	523,537	503,481
Accounts receivable - trade, net	1,420,403	1,343,368
Accounts Receivable from Sanofi	221,078	92,989
Accounts receivable from Bayer	203,066	175,263
Inventories	554,320	399,356
Prepaid expenses and other current assets	193,334	130,528
Total current assets	3,860,051	3,180,188
Marketable securities	1,064,677	864,260
Property, Plant, and Equipment, Net	2,261,702	2,083,421
Deferred tax assets	882,980	825,303
Other assets	36,963	20,294
Total assets	8,106,373	6,973,466
Current liabilities:
Accounts payable and accrued expenses	716,364	879,096
Capital and facility lease obligations, current	0	129,557
Deferred revenue from Sanofi, current portion	184,452	115,267
Deferred Revenue, Current	127,804	116,397
Other current liabilities	397	1,178
Total current liabilities	1,029,017	1,241,495
Capital and facility lease obligations	701,173	351,569
Deferred revenue from Sanofi	443,904	503,474
Deferred Revenue, Noncurrent	295,621	327,298
Other long-term liabilities	115,920	100,385
Total liabilities	2,585,635	2,524,221
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,449,622	3,029,993
Retained earnings	2,384,897	1,748,222
Accumulated other comprehensive income (loss)	2,348	(12,840)
Treasury stock	(316,240)	(316,240)
Total stockholders' equity	5,520,738	4,449,245
Total liabilities and stockholders' equity	8,106,373	6,973,466
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 109	$ 108